Quality of Life With Arcoxia in Women With Dysmenorrhea (0663-094)

NCT00380627 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 337

Last updated 2024-08-15

No results posted yet for this study

Summary

Allow gynecologists to gain experience with arcoxia for treatment of dysmenorrhea.

Conditions

Interventions

DRUG

MK0663, Arcoxia, etoricoxib / Duration of Treatment: 3 Days

Sponsors & Collaborators

  • Organon and Co

    lead INDUSTRY

Principal Investigators

  • Medical Monitor · Merck Sharp & Dohme LLC

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
25 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-09-01
Primary Completion
2006-01-31
Completion
2006-01-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00380627 on ClinicalTrials.gov